Trials / Completed
CompletedNCT03172845
Optical Coherence Tomography (OCT) Findings and Coronary Bifurcation Lesions
Prevalence of Vulnerable Plaque Its Location and Clinical Significance in Bifurcation Lesions Detected by Optical Coherence Tomography.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 304 (actual)
- Sponsor
- Nanjing First Hospital, Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the clinical prevalence of vulnerable plaque using OCT in patients with coronary bifurcation lesion.
Detailed description
This is a prospective registry study in which patient with bifurcation lesion undergoing baseline coronary angiography, baseline OCT and percutaneous coronary intervention will be studied. OCT is used to assess the prevalence of vulnerable plaque, its location at bifurcation lesions and compare vulnerable plaque related major adverse cardiovascular events (MACE) during one-year follow-up in bifurcation lesions between patients with vulnerable plaque and those without. Relationship between endothelial shear stress and vulnerable plaque. Relationship between bifurcation angle and vulnerable plaque. Group A: presence of vulnerable plaque at the bifurcation Group B: absence of vulnerable plaque at the bifurcation Documentation of immediate post stent OCT and 12 months follow up angiography with OCT will be performed. Immediate post stent OCT to assess successful stent implantation and after 12 months follow up to document year major adverse cardiovascular events (MACE) included myocardial infraction, cardiac death and clinically driven target lesion revascularization, stent thrombosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | percutaneous coronary intervention | percutaneous coronary intervention with drug-eluting stent implantation. |
Timeline
- Start date
- 2017-06-27
- Primary completion
- 2018-06-30
- Completion
- 2019-07-30
- First posted
- 2017-06-01
- Last updated
- 2019-07-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03172845. Inclusion in this directory is not an endorsement.